Vanguard Group
KLDO

Vanguard Group’s Kaleido Biosciences, Inc. Common Stock KLDO Stock Holding History

Vanguard Group’s Portfolio KLDO Stock Details KLDO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-870,602
Closed -$1.44M – 4684
2022
Q1 		$1.44M Sell
870,602
-166,785
-16% -$298K ﹤0.01% 4085
2021
Q4 		$2.48M Buy
1,037,387
+967
+0.1% +$3.94K ﹤0.01% 3963
2021
Q3 		$5.66M Buy
1,036,420
+8,965
+0.9% +$55.6K ﹤0.01% 3575
2021
Q2 		$7.64M Buy
1,027,455
+41,286
+4% +$293K ﹤0.01% 3352
2021
Q1 		$7.99M Buy
986,169
+336,414
+52% +$3.66M ﹤0.01% 3279
2020
Q4 		$5.91M Buy
649,755
+102,844
+19% +$844K ﹤0.01% 3285
2020
Q3 		$6.05M Buy
546,911
+1,530
+0.3% +$10.6K ﹤0.01% 3051
2020
Q2 		$4.05M Buy
545,381
+206,332
+61% +$1.38M ﹤0.01% 3196
2020
Q1 		$2.08M Buy
339,049
+576
+0.2% +$3.76K ﹤0.01% 3300
2019
Q4 		$1.7M Buy
338,473
+21,649
+7% +$138K ﹤0.01% 3493
2019
Q3 		$2.39M Buy
316,824
+225,359
+246% +$1.96M ﹤0.01% 3390
2019
Q2 		$1.06M Buy
+91,465
New +$1.33M ﹤0.01% 3661

Other funds holding KLDO

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Vanguard Group's KLDO Position: Q2 2022 in Review

Vanguard Group sold out of Kaleido Biosciences, Inc. Common Stock (KLDO) in Q2 2022, closing a stake of 870,602 shares — an estimated $1.44M sold.

Vanguard Group first reported a position in KLDO in Q2 2019 and held it in 12 quarters. The position peaked at $7.99M in Q1 2021. 3 funds tracked by Wall St. Rank hold KLDO as of Q2 2022.

  • Vanguard Group reported no remaining Kaleido Biosciences, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Vanguard Group sold 870,602 Kaleido Biosciences, Inc. Common Stock shares in Q2 2022, an estimated $1.44M.
  • Vanguard Group first reported a position in Kaleido Biosciences, Inc. Common Stock in Q2 2019 and held it in 12 quarters.
  • Vanguard Group's Kaleido Biosciences, Inc. Common Stock position peaked at $7.99M in Q1 2021.
  • 3 funds tracked by Wall St. Rank held Kaleido Biosciences, Inc. Common Stock as of Q2 2022.

Based on Vanguard Group's 13F filing for Q2 2022, filed 12 Aug 2022.